Drugs in the Pipeline, News Rilzabrutinib Fails in Phase 3 Pemphigus Trial Publish Date September 9, 2021 Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
Drugs in the Pipeline Tezepelumab BLA Submitted for Severe Asthma Publish Date May 10, 2021 The BLA submission is supported by data from the PATHFINDER clinical program.
Drugs in the Pipeline Dupilumab Under Review for Pediatric Asthma Publish Date March 4, 2021 The submission was based on data from the double-blind, placebo-controlled VOYAGE trial.